Safety and tolerability
toxicities, hypertension, mucositis, Treatment-emergent adverse
SINUS BRADYCARDIA, HYPERTENSION, MUCOSITIS, ADVERSE EVENTS
All 14 patients were evaluated for safety. Overall, 13 (92.9%) patients had treatment-emergent AEs (TEAEs) during the study (Table 
Treatment-emergent adverse events (affecting ≥ 10% of patients in either treatment group)Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; α-HBDH, alpha-hydroxybutyrate-dehydrogenase.Four patients experienced treatment interruptions and dose reductions due to SYHA1813-related toxicities, which were grade 2 sinus bradycardia, grade 2 platelet count decreased, grade 3 mucositis oral, and grade 4 hypertension. Serious adverse events considered to be related to SYHA1813 treatment were reported for one (7.1%) patient with grade 4 hypertension in the 30-mg group. No grade 5 AEs occurred.